In tamoxifen-resistant breast cancer, cs78 binds to a variant form of CD44 on the cell surface and stabilizes it, as treatment with antibodies against GRP78 reduces cell surface CD44 protein levels, leading to F-actin disorganization and loss of cell attachment and spreading (69). This evidence concerns the gene HSPA5 and breast cancer.